Cell & Gene Therapy
Cell & Gene Therapy CRO Services for Complex Global Development
Premier Research (Premier) is a global CRO supporting cell, gene and RNA therapy innovators with integrated, end-to-end services spanning regulatory, nonclinical, CMC, clinical operations, safety, data, quality, and commercial strategy. Our senior-led, multidisciplinary team is purpose-built for CGT. Our approach is rooted in three pillars: a dedicated focus on advanced therapies; a tailored, high-touch approach with global reach; and integrated regulatory and clinical expertise. Together, these strengths help sponsors mitigate risks and navigate complexities to maximize asset value and move therapies closer to patients.
100+
CGT projects conducted in last 5 years
70%
Of projects in Phase II/III
400
Sites initiated
1,000+
Patients reached
Cell & Gene Therapy Capabilities
Regulatory, Nonclinical & IND-Enabling Strategy
Guidance on nonclinical planning, IND/CTA strategy and preparation, accelerated approval opportunities (Fast Track, RMAT and Breakthrough Designations), and quality-driven regulatory strategies that facilitate smooth agency interactions and submission readiness.
Learn MoreTechnical CMC Services
Comprehensive and phase-appropriate chemistry, manufacturing, and controls (CMC) services built on quality-by-design principles, including biologics submission assessment, target product profiles, risk management, scale-up and post-approval strategy.
Learn MoreClinical Trial Design, Operations & Site Support
End-to-end CGT trial delivery supported by rigorous GxP-compliant processes and quality oversight from protocol development and site activation through logistics management, patient engagement, retention, and long-term follow-up.
Learn MoreMedical Monitoring and PV Strategy
Integrated monitoring, pharmacovigilance, immunogenicity risk management, and long-term follow-up by CGT specialists for proactive safety oversight and rapid quality-driven signal detection that ensures patient protection throughout development.
Learn MoreIntegrated Guidance for Navigating CGT Complexity
Cell and gene therapy development requires more than conventional clinical trial execution. These programs often involve evolving regulatory expectations, specialized CMC considerations, limited patient populations, invasive or complex administration procedures, immunogenicity and patient safety concerns, high-touch site requirements, and long-term follow-up obligations. Success requires a development partner with specialized advanced therapy expertise, strategic guidance, and the flexibility to adapt to each program's unique needs. Premier brings together CGT-specialized regulatory, clinical, medical, CMC, nonclinical, data, safety, and operational experts to help sponsors move from early development planning through clinical delivery. Our senior-led teams have deep CGT development expertise. They combine a high-touch operating model with seamless collaboration across all critical functions to help sponsors navigate challenges, make informed decisions, and maximize asset value.
Cell & Gene Therapy
Meet the Experts
Kenneth Ndugga-Kabuye, M.D., FACMG
Vice President, Cell & Gene Therapy
Dr. Ken Ndugga-Kabuye is Vice President, Cell & Gene Therapy at Premier Research. He brings direct experience supporting drug development candidates for clinical studies leveraging innovative approaches in the treatment of disease, inclusive of cell and gene therapies, synthetic biotics, RNA therapies, and enzyme replacement therapies. In previous roles, Dr. Ndugga-Kabuye has supported CRO and biotechnology clients in the ATMP space. Dr. Ndugga-Kabuye is a clinical geneticist with residency and fellowship training in medical genetics and genomics from the University of Washington in Seattle, WA, US. He is board certified by the American Board of Medical Genetics and Genomics in Clinical Genetics and Genomics. He holds a medical license in Washington State and California. He is a Diplomate of the American Board of Medical Genetics and Genomics. He is a member of the American Society of Human Genetics (ASHG), the European Society of Human Genetics (ESHG), the American College of Medical Genetics (ACMG), the African Society of Human Genetics (AfSHG), the American Medical Association (AMA) and the American Academy of Pediatrics (AAP).
Learn more
Jessica Merryfield
Vice President, Project Delivery, Cell & Gene Therapy
Jessica Merryfield has been involved in global clinical research for more than 20 years, specializing in rare diseases for the last 10 years. As vice president, gene and cell therapy; Ms. Merryfield advises, consults, plans, and directs the design and strategy for prospective and ongoing gene and cell therapy studies. In her role, she provides operational excellence by driving best practices, identifying global needs for innovation and improvements, and leading Premier’s Continuous Learning Program for Advanced Therapeutics. Through stakeholder engagement and cross-functional management, Ms. Merryfield operates at a strategic support level for complex, critical therapeutically aligned programs. She coordinates strategic direction and delivery for gene and cell therapy with Premier’s innovative partners, including regulatory and statistical consulting, therapeutic experts, patient engagement, and strategic development. Ms. Merryfield has extensive experience in phase 1-4 studies, including autosomal, neurological, metabolic, and hematology disease utilizing innovative precision medicine technologies. Her key experience areas include pediatrics, rare/ultra-rare disease, cardiology, immunology/autoimmune disorders, dermatology, and CNS.
Learn more
Paulla Dennis
Executive Director, Program Strategy, Rare Disease, Pediatrics, Cell & Gene Therapy
Paulla Dennis has been dedicated to rare disease and pediatric clinical research for more than 25 years, specializing in gene therapy for the last 10+ years. She is highly experienced in operational delivery after spending 17 years at a pediatric hospital running the Clinical Research Services group, where she delivered pivotal studies in several rare pediatric disorders inclusive of gene therapies. Paulla has an additional 8 years’ experience in the CRO setting in startup project management as well as in program strategy, delivering rare, pediatric disease and advanced therapies studies. As Executive Director, Program Strategy, Paulla advises, consults, plans, and directs the design and strategy for prospective and ongoing rare, pediatric, and gene and cell therapy studies. In her current role, she provides strategies and solutions for operational excellence in this complex clinical research setting with a focus on patient and family pathway planning and comprehensive site assessment and educational support. Paulla has extensive experience in phase 1-4 studies in a global setting, including autosomal, neurological, metabolic, and endocrine diseases. Her key experience areas include rare/ultra-rare disease, pediatrics, gene therapies, and neurological (neuropsychological, neurodegenerative, and neuromuscular) indications.
Learn more
Greg Meyer, RAC, CQA
Vice President, Regulatory Affairs
Greg Meyer has been in the pharma, biopharma and medical device industry for over 30 years and has gained regulatory approvals in more than 20 countries. He has represented companies during numerous interactions with the FDA, European national and EU regulators, and the Australian TGA and has worked on the development, submission, and commercialization of NMEs and 505(b)(2) products in oncology, neurology, and dermatology. His specialty areas include, cell and gene therapy, biologics and drug-device combination products.
Learn more
Olu Aloba, Ph.D.
Vice President, CMC Services
Dr. Aloba has more than 25 years of leadership experience in pharmaceutical research and development, pharmaceutical technology, and regulatory strategy. He is a subject matter expert in drug product development, with special expertise in the application of quality-by-design (QbD) to formulation and process development, analytical development, and development strategy. He is a registered pharmacist and holds a US Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society. Dr. Aloba joined Premier in 2014 and, in his current role, leads Premier’s Chemistry Manufacturing and Controls (CMC) service offerings focusing on pharmaceutical development strategizing, planning, execution, and documentation in support of drug development programs for Premier’s clients. He also serves as senior technical advisor on Premier’s drug, device, and biologics initiatives and is responsible for continuing development of the pharmaceutical quality expertise, knowledgebase, and policy at Premier.
Learn more
Angi Robinson
Senior Vice President, Specialty Areas (Rare Disease, Pediatrics, Cell & Gene Therapy)
Angi Robinson has been designing and conducting specialty studies, including pediatric and rare disease studies, for more than 22 years. She has provided strategy, oversight, and full management support for rare disease studies at Premier Research for over 18 years, including global programs in ultra-rare indications. Ms. Robinson has a thorough understanding of drug development with extensive supervisory experience and management in conducting registrational-enabling clinical trials for orphan drugs. Ms. Robinson’s experience encompasses complex study designs such as PK/PD and adaptive design, and she has worked with products granted expedited designations by the agencies like FDA Fast Track, Breakthrough Therapy and PRIME designations — including advanced medicines. Specifically in orphan drugs, Ms. Robinson has supported eight products resulting in FDA and EMA approval. Ms. Robinson earned a bachelor’s degree in cell and molecular biology from Tulane University in New Orleans, LA.
Learn moreFAQs
Find answers to common questions about our cell and gene therapy expertise.
CGT trials often involve specialized sites, complex administration procedures, limited patient populations, product handling requirements, chain-of-custody tracking, chain-of-identity tracking, cryopreservation, apheresis scheduling, manufacturing coordination, and long-term follow-up. These requirements create operational risks that must be addressed early in the development plan.
Premier provides sponsors with senior-led, integrated teams that combine regulatory, clinical, CMC, quality, and operational expertise to address the complexity of CGT development across the full product lifecycle. From IND strategy and accelerated approval planning to manufacturing coordination, site activation, chain-of-custody management, and long-term follow-up, our team helps sponsors anticipate risks, maintain quality and GxP compliance, and navigate evolving requirements with confidence. Our focus on advanced therapies, high-touch partnerships, and integrating global regulatory and clinical expertise ensures more efficient trial execution.
Premier supports cell therapies and gene therapies across multiple modalities, including CAR-T, TILs, NK cells, stem cells, autologous and allogeneic cell therapies, in vivo gene therapies, and ex vivo gene-modified cell therapies. Our experience includes viral and non-viral approaches such as AAV, LVV, adenovirus, LNPs, and other non-viral platforms.
Premier helps sponsors define IND strategy, select regulatory pathways, prepare IND/CTA submissions, evaluate accelerated approval opportunities, pursue designations such as Fast Track and RMAT where appropriate, and prepare for regulatory agency interactions, including strategies for addressing a clinical hold.
Premier supports logistics planning for autologous and allogeneic cell therapies, including vein-to-vein workflows, site preparation, chain-of-custody tracking, cryopreservation considerations, apheresis coordination, and risk mitigation around manufacturing variability and adverse event management.
Gene therapies may produce long-acting or durable effects, which means sponsors often need structured long-term follow-up to monitor safety, durability, patient outcomes, and regulatory commitments. Premier helps sponsors design follow-up strategies that support compliance while reducing patient burden and improving retention.
CMC strategy is central to CGT development because product quality, manufacturing consistency, process changes, scale-up, comparability, delivery systems, and post-approval changes can affect regulatory expectations and clinical execution. Premier helps sponsors align CMC planning with clinical and regulatory strategy.
Yes. Premier has CGT experience across rare genetic disorders, oncology, neurology, and other therapeutic areas. Our teams combine therapeutic knowledge with advanced therapy operations to address disease-specific regulatory, clinical, safety, recruitment, and trial design challenges.